Just two cans of soft drink per week could increase your cancer risk by 18% according to a new, French study.
The study has been published in the British Medical Journal – revealing there may be a link between the amount of sugary drinks (including fruit juices and fizzy drinks) consumed and an individual’s risk of developing cancer.
The research, which followed more than 100,000 people for five years, suggests an extra 100ml of sugary drinks a day could lead to an 18% increase in the risk of cancer.
While a causal link is yet to be proven, Ancon Medical, which specialises in non-invasive screening and diagnosis, says more research is needed to clarify the health risks of consuming large amounts of sugar in drinks.
Of the 2,193 cancers found during the study, 693 were breast cancers, 291 were prostate cancers and 166 were colorectal cancers.
Ancon Medical says this is concerning as these are some of the most lethal cancers when not caught early.
For example, when breast cancer is caught early in stages zero or one, the five-year survival rate is close to 100%. Whereas the five-year survival rate for breast cancer is as low as 22% when it is left to reach stage four. Similarly, the survival rate for prostate cancer at stage one is almost 100%, falling to around 87% in stage four.
Ancon Medical claims the discrepancy in survivability between the stages demonstrates the importance of diagnosing cancers at a point when they are still localised and relatively simple to treat.
Wesley Baker, CEO of ANCON Medical, said: “This research, while preliminary, demonstrates the huge amount that is still to be learnt about cancers, their risk factors and causes.
“Before more research can be reliably conducted, which often takes years in the field of epidemiology, we must ensure that cancers are as survivable as possible through treatment and early diagnosis.
“Cancers that are caught in the early stages are easier to treat and patients who are diagnosed early have a far greater chance of surviving more than five years.
“With this in mind, there is a clear and present need for cutting-edge technologies that are relatively inexpensive to use and can provide an accurate diagnosis during that crucial period of time when cancers are in their early stages.
“Diagnostic technology that can keep up with the changing treatment landscape will soon find themselves at the forefront of the movement to increase patient survivability.”
ANCON Medical’s revolutionary Nanoparticle Biomarker Tagging (NBT) technology allows for quick, accurate and cheap diagnosis, with a huge reduction in the number of false positives compared to traditional diagnosis methods.
The technology analyses a patient’s breath to detect unique biological markers that indicate the presence of cancer, as well as the stage it is at. NBT technology can provide diagnoses in as little as ten minutes, all while being less expensive to use and more accurate than current technologies